var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FTTBWENIN%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FTTBWENIN%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FTTBWENIN%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2017\n \n \n (58)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n An audit of coagulation screening in patients presenting to the emergency department for potential stroke thrombolysis: Stroke thrombolysis and point-of-care.\n \n \n \n \n\n\n \n Thorne, K.; McNaughton, H.; and Weatherall, M.\n\n\n \n\n\n\n Internal Medicine Journal, 47(2): 189–193. February 2017.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"AnPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{thorne_audit_2017,\n\ttitle = {An audit of coagulation screening in patients presenting to the emergency department for potential stroke thrombolysis: {Stroke} thrombolysis and point-of-care},\n\tvolume = {47},\n\tissn = {14440903},\n\tshorttitle = {An audit of coagulation screening in patients presenting to the emergency department for potential stroke thrombolysis},\n\turl = {http://doi.wiley.com/10.1111/imj.13323},\n\tdoi = {10.1111/imj.13323},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-09-14},\n\tjournal = {Internal Medicine Journal},\n\tauthor = {Thorne, Katie and McNaughton, Harry and Weatherall, Mark},\n\tmonth = feb,\n\tyear = {2017},\n\tnote = {Number: 2},\n\tpages = {189--193},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The Taking Charge After Stroke (TaCAS) study protocol: a multicentre, investigator-blinded, randomised controlled trial comparing the effect of a single Take Charge session, two Take Charge sessions and control intervention on health-related quality of life 12 months after stroke for non-Māori, non-Pacific adult New Zealanders discharged to community living.\n \n \n \n \n\n\n \n Fu, V. W. Y.; Weatherall, M.; and McNaughton, H.\n\n\n \n\n\n\n BMJ Open, 7(5): e016512. May 2017.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fu_taking_2017,\n\ttitle = {The {Taking} {Charge} {After} {Stroke} ({TaCAS}) study protocol: a multicentre, investigator-blinded, randomised controlled trial comparing the effect of a single {Take} {Charge} session, two {Take} {Charge} sessions and control intervention on health-related quality of life 12 months after stroke for non-{Māori}, non-{Pacific} adult {New} {Zealanders} discharged to community living},\n\tvolume = {7},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {The {Taking} {Charge} {After} {Stroke} ({TaCAS}) study protocol},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2017-016512},\n\tdoi = {10.1136/bmjopen-2017-016512},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-09-14},\n\tjournal = {BMJ Open},\n\tauthor = {Fu, Vivian Wai Yin and Weatherall, Mark and McNaughton, Harry},\n\tmonth = may,\n\tyear = {2017},\n\tnote = {Number: 5},\n\tpages = {e016512},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial.\n \n \n \n\n\n \n Young, P. J.; Bailey, M. J.; Beasley, R. W.; Freebairn, R. C.; Hammond, N. E.; Haren, F. M. P. v.; Harward, M. L.; Henderson, S. J.; Mackle, D. M.; McArthur, C. J.; McGuinness, S. P.; Myburgh, J. A.; Saxena, M. K.; Turner, A.; Webb, S. A. R.; Bellomo, R.; and The ANZICS Clinical Trials Group\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 19(1): 81–87. March 2017.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_protocol_2017,\n\ttitle = {Protocol and statistical analysis plan for the {Randomised} {Evaluation} of {Active} {Control} of {Temperature} versus {Ordinary} {Temperature} {Management} ({REACTOR}) trial},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tabstract = {BACKGROUND: Body temperature can be reduced in febrile patients in the intensive care unit using medicines and physical cooling devices, but it is not known whether systematically preventing and treating fever reduces body temperature compared with standard care.\nOBJECTIVE: To describe the study protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial.\nDESIGN, SETTING AND PARTICIPANTS: Protocol for a phase II, multicentre trial to be conducted in Australian and New Zealand ICUs admitting adult patients. We will recruit 184 adults without acute brain injury who are expected to be ventilated in the ICU beyond the day after randomisation. We will use open, random, parallel assignment to systematic prevention and treatment of fever, or to standard temperature management.\nMAIN OUTCOME MEASURES: The primary end point will be mean body temperature, calculated from body temperatures measured 6-hourly for 7 days (168 hours) or until ICU discharge, whichever is sooner. Secondary end points are ICU-free days, in-hospital and cause-specific mortality (censored at Day 90) and survival time to Day 90 (censored at hospital discharge).\nRESULTS AND CONCLUSIONS: The trial will determine whether active temperature control reduces body temperature compared with standard care. It is primarily being conducted to establish whether a phase III trial with a patient-centred end point of Day 90 mortality is justified and feasible.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bailey, Michael J. and Beasley, Richard W. and Freebairn, Ross C. and Hammond, Naomi E. and Haren, Frank M. P. van and Harward, Meg L. and Henderson, Seton J. and Mackle, Diane M. and McArthur, Colin J. and McGuinness, Shay P. and Myburgh, John A. and Saxena, Manoj K. and Turner, Anne and Webb, Steve A. R. and Bellomo, Rinaldo and {The ANZICS Clinical Trials Group}},\n\tmonth = mar,\n\tyear = {2017},\n\tpmid = {28215136},\n\tnote = {Number: 1},\n\tkeywords = {Clinical Protocols, Fever, Humans, Intensive Care Units, Research Design},\n\tpages = {81--87},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Body temperature can be reduced in febrile patients in the intensive care unit using medicines and physical cooling devices, but it is not known whether systematically preventing and treating fever reduces body temperature compared with standard care. OBJECTIVE: To describe the study protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial. DESIGN, SETTING AND PARTICIPANTS: Protocol for a phase II, multicentre trial to be conducted in Australian and New Zealand ICUs admitting adult patients. We will recruit 184 adults without acute brain injury who are expected to be ventilated in the ICU beyond the day after randomisation. We will use open, random, parallel assignment to systematic prevention and treatment of fever, or to standard temperature management. MAIN OUTCOME MEASURES: The primary end point will be mean body temperature, calculated from body temperatures measured 6-hourly for 7 days (168 hours) or until ICU discharge, whichever is sooner. Secondary end points are ICU-free days, in-hospital and cause-specific mortality (censored at Day 90) and survival time to Day 90 (censored at hospital discharge). RESULTS AND CONCLUSIONS: The trial will determine whether active temperature control reduces body temperature compared with standard care. It is primarily being conducted to establish whether a phase III trial with a patient-centred end point of Day 90 mortality is justified and feasible.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The Plasma-Lyte 148 v Saline (PLUS) study protocol: a multicentre, randomised controlled trial of the effect of intensive care fluid therapy on mortality.\n \n \n \n\n\n \n Hammond, N. E.; Bellomo, R.; Gallagher, M.; Gattas, D.; Glass, P.; Mackle, D.; Micallef, S.; Myburgh, J.; Saxena, M.; Taylor, C.; Young, P.; and Finfer, S.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 19(3): 239–246. September 2017.\n Number: 3\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{hammond_plasma-lyte_2017,\n\ttitle = {The {Plasma}-{Lyte} 148 v {Saline} ({PLUS}) study protocol: a multicentre, randomised controlled trial of the effect of intensive care fluid therapy on mortality},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tshorttitle = {The {Plasma}-{Lyte} 148 v {Saline} ({PLUS}) study protocol},\n\tabstract = {BACKGROUND: 0.9\\% sodium chloride (saline) is the most commonly administered resuscitation fluid on a global basis but emerging evidence suggests that its high chloride content may have important adverse effects.\nOBJECTIVE: To describe the study protocol for the Plasma- Lyte 148 v Saline study, which will test the hypothesis that in critically ill adult patients the use of Plasma-Lyte 148 (a buffered crystalloid solution) for fluid therapy results in different 90-day all-cause mortality when compared with saline.\nDESIGN AND SETTING: We will conduct this multicentre, blinded, randomised controlled trial in approximately 50 intensive care units in Australia and New Zealand. We will randomly assign 8800 patients to either Plasma-Lyte 148 or saline for all resuscitation fluid, maintenance fluid and compatible drug dilution therapy while in the ICU for up to 90 days after randomisation.\nOUTCOME MEASURES: The primary outcome is 90-day all-cause mortality; secondary outcomes include mean and peak creatinine concentration, incidence of renal replacement therapy, incidence and duration of vasoactive drug treatment, duration of mechanical ventilation, ICU and hospital length of stay, and quality of life and health services use at 6 months.\nRESULTS AND CONCLUSIONS: The PLUS study will provide high-quality data on the comparative safety and efficacy of Plasma-Lyte 148 compared with saline for resuscitation and compatible crystalloid fluid therapy in critically ill adult patients.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Hammond, Naomi E. and Bellomo, Rinaldo and Gallagher, Martin and Gattas, David and Glass, Parisa and Mackle, Diane and Micallef, Sharon and Myburgh, John and Saxena, Manoj and Taylor, Colman and Young, Paul and Finfer, Simon},\n\tmonth = sep,\n\tyear = {2017},\n\tpmid = {28866974},\n\tnote = {Number: 3},\n\tkeywords = {Australia, Creatinine, Critical Illness, Fluid Therapy, Gluconates, Health Services, Humans, Intensive Care Units, Length of Stay, Magnesium Chloride, Mortality, New Zealand, Potassium Chloride, Quality of Life, Renal Replacement Therapy, Respiration, Artificial, Resuscitation, Sodium Acetate, Sodium Chloride, Time Factors, Vasoconstrictor Agents, Vasodilator Agents},\n\tpages = {239--246},\n}\n\n
\n
\n\n\n
\n BACKGROUND: 0.9% sodium chloride (saline) is the most commonly administered resuscitation fluid on a global basis but emerging evidence suggests that its high chloride content may have important adverse effects. OBJECTIVE: To describe the study protocol for the Plasma- Lyte 148 v Saline study, which will test the hypothesis that in critically ill adult patients the use of Plasma-Lyte 148 (a buffered crystalloid solution) for fluid therapy results in different 90-day all-cause mortality when compared with saline. DESIGN AND SETTING: We will conduct this multicentre, blinded, randomised controlled trial in approximately 50 intensive care units in Australia and New Zealand. We will randomly assign 8800 patients to either Plasma-Lyte 148 or saline for all resuscitation fluid, maintenance fluid and compatible drug dilution therapy while in the ICU for up to 90 days after randomisation. OUTCOME MEASURES: The primary outcome is 90-day all-cause mortality; secondary outcomes include mean and peak creatinine concentration, incidence of renal replacement therapy, incidence and duration of vasoactive drug treatment, duration of mechanical ventilation, ICU and hospital length of stay, and quality of life and health services use at 6 months. RESULTS AND CONCLUSIONS: The PLUS study will provide high-quality data on the comparative safety and efficacy of Plasma-Lyte 148 compared with saline for resuscitation and compatible crystalloid fluid therapy in critically ill adult patients.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults.\n \n \n \n \n\n\n \n Cooper, D. J.; McQuilten, Z. K.; Nichol, A.; Ady, B.; Aubron, C.; Bailey, M.; Bellomo, R.; Gantner, D.; Irving, D. O.; Kaukonen, K.; McArthur, C.; Murray, L.; Pettilä, V.; and French, C.\n\n\n \n\n\n\n New England Journal of Medicine, 377(19): 1858–1867. November 2017.\n Number: 19\n\n\n\n
\n\n\n\n \n \n \"AgePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{cooper_age_2017,\n\ttitle = {Age of {Red} {Cells} for {Transfusion} and {Outcomes} in {Critically} {Ill} {Adults}},\n\tvolume = {377},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1707572},\n\tdoi = {10.1056/NEJMoa1707572},\n\tlanguage = {en},\n\tnumber = {19},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Cooper, D. James and McQuilten, Zoe K. and Nichol, Alistair and Ady, Bridget and Aubron, Cécile and Bailey, Michael and Bellomo, Rinaldo and Gantner, Dashiell and Irving, David O. and Kaukonen, Kirsi-Maija and McArthur, Colin and Murray, Lynne and Pettilä, Ville and French, Craig},\n\tmonth = nov,\n\tyear = {2017},\n\tnote = {Number: 19},\n\tpages = {1858--1867},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Angiotensin II for the Treatment of Vasodilatory Shock.\n \n \n \n \n\n\n \n Khanna, A.; English, S. W.; Wang, X. S.; Ham, K.; Tumlin, J.; Szerlip, H.; Busse, L. W.; Altaweel, L.; Albertson, T. E.; Mackey, C.; McCurdy, M. T.; Boldt, D. W.; Chock, S.; Young, P. J.; Krell, K.; Wunderink, R. G.; Ostermann, M.; Murugan, R.; Gong, M. N.; Panwar, R.; Hästbacka, J.; Favory, R.; Venkatesh, B.; Thompson, B. T.; Bellomo, R.; Jensen, J.; Kroll, S.; Chawla, L. S.; Tidmarsh, G. F.; and Deane, A. M.\n\n\n \n\n\n\n New England Journal of Medicine, 377(5): 419–430. August 2017.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"AngiotensinPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{khanna_angiotensin_2017,\n\ttitle = {Angiotensin {II} for the {Treatment} of {Vasodilatory} {Shock}},\n\tvolume = {377},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1704154},\n\tdoi = {10.1056/NEJMoa1704154},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Khanna, Ashish and English, Shane W. and Wang, Xueyuan S. and Ham, Kealy and Tumlin, James and Szerlip, Harold and Busse, Laurence W. and Altaweel, Laith and Albertson, Timothy E. and Mackey, Caleb and McCurdy, Michael T. and Boldt, David W. and Chock, Stefan and Young, Paul J. and Krell, Kenneth and Wunderink, Richard G. and Ostermann, Marlies and Murugan, Raghavan and Gong, Michelle N. and Panwar, Rakshit and Hästbacka, Johanna and Favory, Raphael and Venkatesh, Balasubramanian and Thompson, B. Taylor and Bellomo, Rinaldo and Jensen, Jeffrey and Kroll, Stew and Chawla, Lakhmir S. and Tidmarsh, George F. and Deane, Adam M.},\n\tmonth = aug,\n\tyear = {2017},\n\tnote = {Number: 5},\n\tpages = {419--430},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Venous haemodynamics of Jet Impulse Technology within a lower limb fibreglass cast: a randomized controlled trial.\n \n \n \n\n\n \n Schwarzenlander, K.; Buchanan, S.; Mackintosh, S.; Braithwaite, I.; and De Ruyter, B.\n\n\n \n\n\n\n JRSM Open, 8(2): 205427041668174. 2017.\n Number: 2\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{schwarzenlander_venous_2017,\n\ttitle = {Venous haemodynamics of {Jet} {Impulse} {Technology} within a lower limb fibreglass cast: a randomized controlled trial},\n\tvolume = {8},\n\tissn = {2054-2704},\n\tdoi = {10.1177/2054270416681746},\n\tabstract = {Objectives: We investigated popliteal venous haemodynamics of the VenaJet Jet Impulse Technology system within a below-knee fibreglass cast. Design: Randomized controlled trial. Participants: Twenty-four healthy participants aged 18–54 had both feet placed within the Jet Impulse Technology system and were randomised for one or other leg to be within a below-knee fibreglass cast. Setting: Pacific Radiology, Lower Hutt, Wellington Main outcome measures: The primary outcome variable was peak systolic velocity (cm/s) compared between legs with and without the cast at 60 min (after 10 min Jet Impulse Technology activation), using a mixed linear model and a non-inferiority bound of 4.8 cm/s. Secondary outcome variables were the difference in peak systolic velocity between the casted limb and the non-casted limb at baseline and 40 min after casting, and the difference in mean flow velocity (cm/s), vein diameter (mm), and total volume flow (L/min) between the casted limb and the non-casted limb at baseline, 40 and 60 min. Results: The mean (standard deviation) peak systolic velocity was 4.6(1.5), 4.8(1.1), 28.8(16.1), and 4.3(1.2), 4.8(1.4) and 29.3(19.0) cm/s at baseline, 40 and 60 min in the casted and non-casted leg, respectively. The difference (95\\% confidence interval) between cast and no-cast at 60 min was −0.8 (−6.5 to 4.9) cm/s, P = 0.78. The peak systolic velocity, flow velocity and total volume flow at 40 min were not statistically significantly different from baseline for both casted and non-casted limb. Conclusion: In healthy volunteers, the popliteal venous haemodynamics of the Jet Impulse Technology system was similar between the legs with and without a below-knee fibreglass cast. In-cast Jet Impulse Technology may provide a non-pharmacological option for venous thromboembolism prophylaxis for lower-limb cast-immobility.},\n\tnumber = {2},\n\tjournal = {JRSM Open},\n\tauthor = {Schwarzenlander, Kerstin and Buchanan, Samantha and Mackintosh, Stephen and Braithwaite, Irene and De Ruyter, Bernadette},\n\tyear = {2017},\n\tnote = {Number: 2},\n\tpages = {205427041668174},\n}\n\n
\n
\n\n\n
\n Objectives: We investigated popliteal venous haemodynamics of the VenaJet Jet Impulse Technology system within a below-knee fibreglass cast. Design: Randomized controlled trial. Participants: Twenty-four healthy participants aged 18–54 had both feet placed within the Jet Impulse Technology system and were randomised for one or other leg to be within a below-knee fibreglass cast. Setting: Pacific Radiology, Lower Hutt, Wellington Main outcome measures: The primary outcome variable was peak systolic velocity (cm/s) compared between legs with and without the cast at 60 min (after 10 min Jet Impulse Technology activation), using a mixed linear model and a non-inferiority bound of 4.8 cm/s. Secondary outcome variables were the difference in peak systolic velocity between the casted limb and the non-casted limb at baseline and 40 min after casting, and the difference in mean flow velocity (cm/s), vein diameter (mm), and total volume flow (L/min) between the casted limb and the non-casted limb at baseline, 40 and 60 min. Results: The mean (standard deviation) peak systolic velocity was 4.6(1.5), 4.8(1.1), 28.8(16.1), and 4.3(1.2), 4.8(1.4) and 29.3(19.0) cm/s at baseline, 40 and 60 min in the casted and non-casted leg, respectively. The difference (95% confidence interval) between cast and no-cast at 60 min was −0.8 (−6.5 to 4.9) cm/s, P = 0.78. The peak systolic velocity, flow velocity and total volume flow at 40 min were not statistically significantly different from baseline for both casted and non-casted limb. Conclusion: In healthy volunteers, the popliteal venous haemodynamics of the Jet Impulse Technology system was similar between the legs with and without a below-knee fibreglass cast. In-cast Jet Impulse Technology may provide a non-pharmacological option for venous thromboembolism prophylaxis for lower-limb cast-immobility.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n β-blockers in exacerbations of COPD: Feasibility of a randomised controlled trial.\n \n \n \n\n\n \n Chang, C.; Wong, C.; Beckert, L.; Shafuddin, E.; Beasley, R.; Young, R.; and J. Hancox, R.\n\n\n \n\n\n\n ERJ Open Research, 3: 90–2016. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{chang_-blockers_2017,\n\ttitle = {β-blockers in exacerbations of {COPD}: {Feasibility} of a randomised controlled trial},\n\tvolume = {3},\n\tdoi = {10.1183/23120541.00090-2016},\n\tjournal = {ERJ Open Research},\n\tauthor = {Chang, Catherina and Wong, Conroy and Beckert, Lutz and Shafuddin, Eskandarain and Beasley, Richard and Young, Robert and J. Hancox, Robert},\n\tyear = {2017},\n\tpages = {90--2016},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Vitamin D and asthma: a case to answer.\n \n \n \n\n\n \n Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n The Lancet Respiratory Medicine, 5(11): 839–840. 2017.\n Number: 11 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_vitamin_2017,\n\ttitle = {Vitamin {D} and asthma: a case to answer},\n\tvolume = {5},\n\tissn = {2213-2600},\n\tnumber = {11},\n\tjournal = {The Lancet Respiratory Medicine},\n\tauthor = {Beasley, Richard and Weatherall, Mark},\n\tyear = {2017},\n\tnote = {Number: 11\nPublisher: Elsevier},\n\tpages = {839--840},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Venous thromboembolic events in critically ill traumatic brain injury patients.\n \n \n \n\n\n \n Skrifvars, M. B; Bailey, M.; Presneill, J.; French, C.; Nichol, A.; Little, L.; Duranteau, J.; Huet, O.; Haddad, S.; and Arabi, Y.\n\n\n \n\n\n\n Intensive care medicine, 43(3): 419–428. 2017.\n Number: 3 Publisher: Springer\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{skrifvars_venous_2017,\n\ttitle = {Venous thromboembolic events in critically ill traumatic brain injury patients},\n\tvolume = {43},\n\tissn = {0342-4642},\n\tnumber = {3},\n\tjournal = {Intensive care medicine},\n\tauthor = {Skrifvars, Markus B and Bailey, Michael and Presneill, Jeffrey and French, Craig and Nichol, Alistair and Little, Lorraine and Duranteau, Jacques and Huet, Olivier and Haddad, Samir and Arabi, Yaseen},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: Springer},\n\tpages = {419--428},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Trends in international asthma mortality: Analysis of data from the WHO Mortality Database from 46 countries (1993-2012).\n \n \n \n\n\n \n Ebmeier, S.; Thayabaran, D.; Braithwaite, I.; Bénamara, C.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The Lancet, 390. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{ebmeier_trends_2017,\n\ttitle = {Trends in international asthma mortality: {Analysis} of data from the {WHO} {Mortality} {Database} from 46 countries (1993-2012)},\n\tvolume = {390},\n\tdoi = {10.1016/S0140-6736(17)31448-4},\n\tjournal = {The Lancet},\n\tauthor = {Ebmeier, Stefan and Thayabaran, Darmiga and Braithwaite, Irene and Bénamara, Clément and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Tranexamic acid in patients undergoing coronary-artery surgery.\n \n \n \n\n\n \n Myles, P. S; Smith, J. A; Forbes, A.; Silbert, B.; Jayarajah, M.; Painter, T.; Cooper, D J.; Marasco, S.; McNeil, J.; and Bussières, J. S\n\n\n \n\n\n\n New England Journal of Medicine, 376(2): 136–148. 2017.\n Number: 2 Publisher: Mass Medical Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{myles_tranexamic_2017,\n\ttitle = {Tranexamic acid in patients undergoing coronary-artery surgery},\n\tvolume = {376},\n\tissn = {0028-4793},\n\tnumber = {2},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Myles, Paul S and Smith, Julian A and Forbes, Andrew and Silbert, Brendan and Jayarajah, Mohandas and Painter, Thomas and Cooper, D James and Marasco, Silvana and McNeil, John and Bussières, Jean S},\n\tyear = {2017},\n\tnote = {Number: 2\nPublisher: Mass Medical Soc},\n\tpages = {136--148},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The rapid and accurate categorisation of critically ill patients (RACE) to identify outcomes of interest for longitudinal studies: a feasibility study.\n \n \n \n\n\n \n Deane, A M; Hodgson, C L; Young, P; Little, L; Singh, V; Poole, A; Young, M; Mackle, D; Lange, K; and Williams, P\n\n\n \n\n\n\n Anaesthesia and intensive care, 45(4): 476–484. 2017.\n Number: 4 Publisher: SAGE Publications Sage UK: London, England\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{deane_rapid_2017,\n\ttitle = {The rapid and accurate categorisation of critically ill patients ({RACE}) to identify outcomes of interest for longitudinal studies: a feasibility study},\n\tvolume = {45},\n\tissn = {0310-057X},\n\tnumber = {4},\n\tjournal = {Anaesthesia and intensive care},\n\tauthor = {Deane, A M and Hodgson, C L and Young, P and Little, L and Singh, V and Poole, A and Young, M and Mackle, D and Lange, K and Williams, P},\n\tyear = {2017},\n\tnote = {Number: 4\nPublisher: SAGE Publications Sage UK: London, England},\n\tpages = {476--484},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The Plasma-Lyte 148 v Saline (PLUS) study protocol: A multicentre, randomised controlled trial of the effect of intensive care fl uid therapy on mortality.\n \n \n \n\n\n \n Hammond, N. E; Bellomo, R.; Gallagher, M.; Gattas, D.; Glass, P.; Mackle, D.; Micallef, S.; Myburgh, J.; Saxena, M.; and Taylor, C.\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(3): 239. 2017.\n Number: 3 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{hammond_plasma-lyte_2017-1,\n\ttitle = {The {Plasma}-{Lyte} 148 v {Saline} ({PLUS}) study protocol: {A} multicentre, randomised controlled trial of the effect of intensive care fl uid therapy on mortality},\n\tvolume = {19},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Hammond, Naomi E and Bellomo, Rinaldo and Gallagher, Martin and Gattas, David and Glass, Parisa and Mackle, Diane and Micallef, Sharon and Myburgh, John and Saxena, Manoj and Taylor, Colman},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {239},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Target oxygen saturation range: 92–96% Versus 94–98%.\n \n \n \n\n\n \n Beasley, R.; Chien, J.; Douglas, J.; Eastlake, L.; Farah, C.; King, G.; Moore, R.; Pilcher, J.; Richards, M.; and Smith, S.\n\n\n \n\n\n\n Respirology, 22(1): 200–202. 2017.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_target_2017,\n\ttitle = {Target oxygen saturation range: 92–96\\% {Versus} 94–98\\%},\n\tvolume = {22},\n\tissn = {1323-7799},\n\tnumber = {1},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Chien, Jimmy and Douglas, James and Eastlake, Leonie and Farah, Claude and King, Gregory and Moore, Rosemary and Pilcher, Janine and Richards, Michael and Smith, Sheree},\n\tyear = {2017},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {200--202},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Statistical analysis plan for the adjunctive corticosteroid treatment in critically ill patients with septic shock (ADRENAL) trial.\n \n \n \n\n\n \n Billot, L.; Venkatesh, B.; Myburgh, J.; Finfer, S.; Cohen, J.; Webb, S.; McArthur, C.; Joyce, C.; Bellomo, R.; and Rhodes, A.\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(2): 183. 2017.\n Number: 2 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{billot_statistical_2017,\n\ttitle = {Statistical analysis plan for the adjunctive corticosteroid treatment in critically ill patients with septic shock ({ADRENAL}) trial},\n\tvolume = {19},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Billot, Laurent and Venkatesh, Balasubramanian and Myburgh, John and Finfer, Simon and Cohen, Jeremy and Webb, Steve and McArthur, Colin and Joyce, Christopher and Bellomo, Rinaldo and Rhodes, Andrew},\n\tyear = {2017},\n\tnote = {Number: 2\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {183},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Sing Your Lungs Out - A community singing group for chronic obstructive pulmonary disease: A 1-year pilot study.\n \n \n \n\n\n \n McNaughton, A.; Weatherall, M.; Williams, M.; McNaughton, H.; Aldington, S.; Williams, G.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open, 7: e014151. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mcnaughton_sing_2017,\n\ttitle = {Sing {Your} {Lungs} {Out} - {A} community singing group for chronic obstructive pulmonary disease: {A} 1-year pilot study},\n\tvolume = {7},\n\tdoi = {10.1136/bmjopen-2016-014151},\n\tjournal = {BMJ Open},\n\tauthor = {McNaughton, Amanda and Weatherall, Mark and Williams, Mathew and McNaughton, Harry and Aldington, Sarah and Williams, Gayle and Beasley, Richard},\n\tyear = {2017},\n\tpages = {e014151},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Restrictive versus liberal fluid therapy in major abdominal surgery (RELIEF): rationale and design for a multicentre randomised trial.\n \n \n \n\n\n \n Myles, P.; Bellomo, R.; Corcoran, T.; Forbes, A.; Wallace, S.; Peyton, P.; Christophi, C.; Story, D.; Leslie, K.; and Serpell, J.\n\n\n \n\n\n\n BMJ open, 7(3): e015358. 2017.\n Number: 3 Publisher: British Medical Journal Publishing Group\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{myles_restrictive_2017,\n\ttitle = {Restrictive versus liberal fluid therapy in major abdominal surgery ({RELIEF}): rationale and design for a multicentre randomised trial},\n\tvolume = {7},\n\tissn = {2044-6055},\n\tnumber = {3},\n\tjournal = {BMJ open},\n\tauthor = {Myles, Paul and Bellomo, Rinaldo and Corcoran, Tomas and Forbes, Andrew and Wallace, Sophie and Peyton, Philip and Christophi, Chris and Story, David and Leslie, Kate and Serpell, Jonathan},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: British Medical Journal Publishing Group},\n\tpages = {e015358},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study.\n \n \n \n\n\n \n Power, S.; Williams, M.; Semprini, A.; Munro, C.; Caswell-Smith, R.; Pilcher, J.; Holliday, M.; Fingleton, J.; Harper, J.; and Hurst, R.\n\n\n \n\n\n\n BMJ open, 7(3): e013850. 2017.\n Number: 3 Publisher: British Medical Journal Publishing Group\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{power_rct_2017,\n\ttitle = {{RCT} of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study},\n\tvolume = {7},\n\tissn = {2044-6055},\n\tnumber = {3},\n\tjournal = {BMJ open},\n\tauthor = {Power, Sharon and Williams, Mathew and Semprini, Alex and Munro, Claire and Caswell-Smith, Rachel and Pilcher, Janine and Holliday, Mark and Fingleton, James and Harper, Jacquie and Hurst, Roger},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: British Medical Journal Publishing Group},\n\tpages = {e013850},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Restrictive or liberal red-cell transfusion for cardiac surgery.\n \n \n \n\n\n \n Mazer, C D.; Whitlock, R. P; Fergusson, D. A; Hall, J.; Belley-Cote, E.; Connolly, K.; Khanykin, B.; Gregory, A. J; de Médicis, É.; and McGuinness, S.\n\n\n \n\n\n\n New England Journal of Medicine, 377(22): 2133–2144. 2017.\n Number: 22 Publisher: Mass Medical Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mazer_restrictive_2017,\n\ttitle = {Restrictive or liberal red-cell transfusion for cardiac surgery},\n\tvolume = {377},\n\tissn = {0028-4793},\n\tnumber = {22},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Mazer, C David and Whitlock, Richard P and Fergusson, Dean A and Hall, Judith and Belley-Cote, Emilie and Connolly, Katherine and Khanykin, Boris and Gregory, Alexander J and de Médicis, Étienne and McGuinness, Shay},\n\tyear = {2017},\n\tnote = {Number: 22\nPublisher: Mass Medical Soc},\n\tpages = {2133--2144},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Nasal high flow therapy and PtCO2 in stable COPD: A randomized controlled cross‐over trial.\n \n \n \n\n\n \n McKinstry, S.; Pilcher, J.; Bardsley, G.; Berry, J.; de Hei, S.; Braithwaite, I.; Fingleton, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 23. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mckinstry_nasal_2017,\n\ttitle = {Nasal high flow therapy and {PtCO2} in stable {COPD}: {A} randomized controlled cross‐over trial},\n\tvolume = {23},\n\tdoi = {10.1111/resp.13185},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Pilcher, Janine and Bardsley, George and Berry, James and de Hei, Susanne and Braithwaite, Irene and Fingleton, James and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: A randomized controlled cross-over trial.\n \n \n \n\n\n \n Pilcher, J.; Eastlake, L.; Richards, M.; Power, S.; Cripps, T.; Bibby, S.; Braithwaite, I.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Respirology (Carlton, Vic.), 22. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_physiological_2017,\n\ttitle = {Physiological effects of titrated oxygen via nasal high-flow cannulae in {COPD} exacerbations: {A} randomized controlled cross-over trial},\n\tvolume = {22},\n\tdoi = {10.1111/resp.13050},\n\tjournal = {Respirology (Carlton, Vic.)},\n\tauthor = {Pilcher, Janine and Eastlake, Leonie and Richards, Michael and Power, Sharon and Cripps, Terrianne and Bibby, Susan and Braithwaite, Irene and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting.\n \n \n \n\n\n \n Semprini, A.; Singer, J.; Shortt, N.; Braithwaite, I.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open, 7: e017766. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{semprini_protocol_2017,\n\ttitle = {Protocol for a randomised controlled trial of 90\\% kanuka honey versus 5\\% aciclovir for the treatment of herpes simplex labialis in the community setting},\n\tvolume = {7},\n\tdoi = {10.1136/bmjopen-2017-017766},\n\tjournal = {BMJ Open},\n\tauthor = {Semprini, Alex and Singer, Joseph and Shortt, Nick and Braithwaite, Irene and Beasley, Richard},\n\tyear = {2017},\n\tpages = {e017766},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial.\n \n \n \n\n\n \n Young, P. J; Bailey, M. J; Beasley, R. W; Freebairn, R. C; Hammond, N. E; van Haren, F. M P; Harward, M. L; Henderson, S. J; Mackle, D. M; and McArthur, C. J\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(1): 81. 2017.\n Number: 1 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_protocol_2017-1,\n\ttitle = {Protocol and statistical analysis plan for the {Randomised} {Evaluation} of {Active} {Control} of {Temperature} versus {Ordinary} {Temperature} {Management} ({REACTOR}) trial},\n\tvolume = {19},\n\tnumber = {1},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Young, Paul J and Bailey, Michael J and Beasley, Richard W and Freebairn, Ross C and Hammond, Naomi E and van Haren, Frank M P and Harward, Meg L and Henderson, Seton J and Mackle, Diane M and McArthur, Colin J},\n\tyear = {2017},\n\tnote = {Number: 1\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {81},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Precision medicine in airway diseases: moving to clinical practice.\n \n \n \n\n\n \n Agustí, A.; Bafadhel, M.; Beasley, R.; Bel, E. H; Faner, R.; Gibson, P. G; Louis, R.; McDonald, V. M; Sterk, P. J; and Thomas, M.\n\n\n \n\n\n\n European Respiratory Journal, 50(4): 1701655. 2017.\n Number: 4 Publisher: Eur Respiratory Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{agusti_precision_2017,\n\ttitle = {Precision medicine in airway diseases: moving to clinical practice},\n\tvolume = {50},\n\tissn = {0903-1936},\n\tnumber = {4},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Agustí, Alvar and Bafadhel, Mona and Beasley, Richard and Bel, Elisabeth H and Faner, Rosa and Gibson, Peter G and Louis, Renaud and McDonald, Vanessa M and Sterk, Peter J and Thomas, Mike},\n\tyear = {2017},\n\tnote = {Number: 4\nPublisher: Eur Respiratory Soc},\n\tpages = {1701655},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Phenotypes of symptomatic airways disease in China and New Zealand.\n \n \n \n\n\n \n Fingleton, J.; Huang, K.; Weatherall, M.; Guo, Y.; Ivanov, S.; Bruijnzeel, P.; Zhang, H.; Wang, W.; Beasley, R.; and Wang, C.\n\n\n \n\n\n\n European Respiratory Journal, 50: 1700957. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fingleton_phenotypes_2017,\n\ttitle = {Phenotypes of symptomatic airways disease in {China} and {New} {Zealand}},\n\tvolume = {50},\n\tdoi = {10.1183/13993003.00957-2017},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Fingleton, James and Huang, Kewu and Weatherall, Mark and Guo, Yanfei and Ivanov, Stefan and Bruijnzeel, Piet and Zhang, Hong and Wang, Wei and Beasley, Richard and Wang, Chen},\n\tyear = {2017},\n\tpages = {1700957},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: an international cross-sectional study.\n \n \n \n\n\n \n Hammond, N. E; Taylor, C.; Finfer, S.; Machado, F. R; An, Y.; Billot, L.; Bloos, F.; Bozza, F.; Cavalcanti, A. B.; and Correa, M.\n\n\n \n\n\n\n PLoS One, 12(5): e0176292. 2017.\n Number: 5 Publisher: Public Library of Science\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{hammond_patterns_2017,\n\ttitle = {Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: an international cross-sectional study},\n\tvolume = {12},\n\tissn = {1932-6203},\n\tnumber = {5},\n\tjournal = {PLoS One},\n\tauthor = {Hammond, Naomi E and Taylor, Colman and Finfer, Simon and Machado, Flavia R and An, YouZhong and Billot, Laurent and Bloos, Frank and Bozza, Fernando and Cavalcanti, Alexandre Biasi and Correa, Maryam},\n\tyear = {2017},\n\tnote = {Number: 5\nPublisher: Public Library of Science},\n\tpages = {e0176292},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Oxygen compared to air driven nebulisers for acute exacerbations of COPD: a randomised controlled trial.\n \n \n \n\n\n \n Bardsley, G.; McKinstry, S.; Pilcher, J.; Fingleton, J.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n In pages PA684, 2017. \n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{bardsley_oxygen_2017,\n\ttitle = {Oxygen compared to air driven nebulisers for acute exacerbations of {COPD}: a randomised controlled trial},\n\tdoi = {10.1183/1393003.congress-2017.PA684},\n\tauthor = {Bardsley, George and McKinstry, Steve and Pilcher, Janine and Fingleton, James and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tpages = {PA684},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n New Zealand asthma guidelines updated.\n \n \n \n\n\n \n Beasley, R.; and Hancox, R. J\n\n\n \n\n\n\n The New Zealand Medical Journal (Online), 130(1466): 7–9. 2017.\n Number: 1466 Publisher: New Zealand Medical Association (NZMA)\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_new_2017,\n\ttitle = {New {Zealand} asthma guidelines updated},\n\tvolume = {130},\n\tissn = {1175-8716},\n\tnumber = {1466},\n\tjournal = {The New Zealand Medical Journal (Online)},\n\tauthor = {Beasley, Richard and Hancox, Robert J},\n\tyear = {2017},\n\tnote = {Number: 1466\nPublisher: New Zealand Medical Association (NZMA)},\n\tpages = {7--9},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Lower limb immobilisation and venous thromboembolism risk: combined case–control studies.\n \n \n \n\n\n \n Braithwaite, I.; Healy, B.; Cameron, L.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n Postgraduate medical journal, 93(1100): 354–359. 2017.\n Number: 1100 Publisher: The Fellowship of Postgraduate Medicine\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{braithwaite_lower_2017,\n\ttitle = {Lower limb immobilisation and venous thromboembolism risk: combined case–control studies},\n\tvolume = {93},\n\tissn = {0032-5473},\n\tnumber = {1100},\n\tjournal = {Postgraduate medical journal},\n\tauthor = {Braithwaite, Irene and Healy, Bridget and Cameron, Laird and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tnote = {Number: 1100\nPublisher: The Fellowship of Postgraduate Medicine},\n\tpages = {354--359},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Longitudinal variation of serum periostin levels in adults with stable asthma.\n \n \n \n\n\n \n Semprini, R.; Caswell-Smith, R.; Fingleton, J.; Holweg, C.; Matthews, J.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Journal of Allergy and Clinical Immunology, 139(5): 1687–1688. 2017.\n Number: 5 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{semprini_longitudinal_2017,\n\ttitle = {Longitudinal variation of serum periostin levels in adults with stable asthma},\n\tvolume = {139},\n\tissn = {0091-6749},\n\tnumber = {5},\n\tjournal = {Journal of Allergy and Clinical Immunology},\n\tauthor = {Semprini, Ruth and Caswell-Smith, Rachel and Fingleton, James and Holweg, Cecile and Matthews, John and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2017},\n\tnote = {Number: 5\nPublisher: Elsevier},\n\tpages = {1687--1688},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Longitudinal variation of serum periostin in adults with stable asthma.\n \n \n \n\n\n \n Semprini, R.; Caswell-Smith, R.; Fingleton, J.; Holweg, C.; Matthews, J; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Journal of Allergy and Clinical Immunology, 139. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{semprini_longitudinal_2017-1,\n\ttitle = {Longitudinal variation of serum periostin in adults with stable asthma},\n\tvolume = {139},\n\tdoi = {10.1016/j.jaci.2016.11.041},\n\tjournal = {Journal of Allergy and Clinical Immunology},\n\tauthor = {Semprini, Ruth and Caswell-Smith, Rachel and Fingleton, James and Holweg, Cécile and Matthews, J and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase.\n \n \n \n\n\n \n Young, P. J; Mackle, D. M; Bailey, M. J; Beasley, R. W; Bennett, V. L; Deane, A. M; Eastwood, G. M; Finfer, S.; Freebairn, R. C; and Litton, E.\n\n\n \n\n\n\n Critical care and resuscitation: journal of the Australasian Academy of Critical Care Medicine, 19(4): 344–354. 2017.\n Number: 4 Publisher: Australasian Medical Publishing Co. Ltd\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_intensive_2017,\n\ttitle = {Intensive care unit randomised trial comparing two approaches to oxygen therapy ({ICU}-{ROX}): results of the pilot phase},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tnumber = {4},\n\tjournal = {Critical care and resuscitation: journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J and Mackle, Diane M and Bailey, Michael J and Beasley, Richard W and Bennett, Victoria L and Deane, Adam M and Eastwood, Glenn M and Finfer, Simon and Freebairn, Ross C and Litton, Edward},\n\tyear = {2017},\n\tnote = {Number: 4\nPublisher: Australasian Medical Publishing Co. Ltd},\n\tpages = {344--354},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI).\n \n \n \n\n\n \n Daley-Yates, P.; Baines, A.; Riddell, K.; Joshi, S.; Jean Bareille, P.; Bardsley, G.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n In pages OA276, 2017. \n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{daley-yates_late_2017,\n\ttitle = {Late {Breaking} {Abstract} - {The} duration of anti-inflammatory action of fluticasone furoate ({FF}) assessed via exhaled nitric oxide ({FeNO}) in asthmatics following administration of {FF}/vilanterol ({VI})},\n\tdoi = {10.1183/1393003.congress-2017.OA276},\n\tauthor = {Daley-Yates, Peter and Baines, Amanda and Riddell, Kylie and Joshi, Shashidhar and Jean Bareille, Philippe and Bardsley, George and Beasley, Richard and Fingleton, James},\n\tyear = {2017},\n\tpages = {OA276},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n High flow or titrated oxygen for obese medical inpatients: A randomised crossover trial.\n \n \n \n\n\n \n Pilcher, J.; Richards, M.; Eastlake, L.; J McKinstry, S.; Bardsley, G.; Jefferies, S.; Braithwaite, I.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n The Medical Journal of Australia, 207: 430–434. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_high_2017,\n\ttitle = {High flow or titrated oxygen for obese medical inpatients: {A} randomised crossover trial},\n\tvolume = {207},\n\tdoi = {10.5694/mja17.00270},\n\tjournal = {The Medical Journal of Australia},\n\tauthor = {Pilcher, Janine and Richards, Michael and Eastlake, Leonie and J McKinstry, Steven and Bardsley, George and Jefferies, Sarah and Braithwaite, Irene and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tpages = {430--434},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Glycaemic control in diabetic ketoacidosis: Too much of a good thing?.\n \n \n \n\n\n \n McArthur, C.\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(3): 195. 2017.\n Number: 3 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mcarthur_glycaemic_2017,\n\ttitle = {Glycaemic control in diabetic ketoacidosis: {Too} much of a good thing?},\n\tvolume = {19},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {McArthur, Colin},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {195},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Fluid management in acute kidney injury.\n \n \n \n\n\n \n Perner, A.; Prowle, J.; Joannidis, M.; Young, P.; Hjortrup, P. B; and Pettilä, V.\n\n\n \n\n\n\n Intensive care medicine, 43(6): 807–815. 2017.\n Number: 6 Publisher: Springer\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{perner_fluid_2017,\n\ttitle = {Fluid management in acute kidney injury},\n\tvolume = {43},\n\tissn = {0342-4642},\n\tnumber = {6},\n\tjournal = {Intensive care medicine},\n\tauthor = {Perner, Anders and Prowle, John and Joannidis, Michael and Young, Paul and Hjortrup, Peter B and Pettilä, Ville},\n\tyear = {2017},\n\tnote = {Number: 6\nPublisher: Springer},\n\tpages = {807--815},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Erythropoietin in patients with traumatic brain injury and extracranial injury—A post hoc analysis of the erythropoietin traumatic brain injury trial.\n \n \n \n\n\n \n Skrifvars, M. B; Bailey, M.; French, C.; Presneill, J.; Nichol, A.; Little, L.; Duranteau, J.; Huet, O.; Haddad, S.; and Arabi, Y.\n\n\n \n\n\n\n Journal of Trauma and Acute Care Surgery, 83(3): 449–456. 2017.\n Number: 3 Publisher: LWW\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{skrifvars_erythropoietin_2017,\n\ttitle = {Erythropoietin in patients with traumatic brain injury and extracranial injury—{A} post hoc analysis of the erythropoietin traumatic brain injury trial},\n\tvolume = {83},\n\tissn = {2163-0755},\n\tnumber = {3},\n\tjournal = {Journal of Trauma and Acute Care Surgery},\n\tauthor = {Skrifvars, Markus B and Bailey, Michael and French, Craig and Presneill, Jeffrey and Nichol, Alistair and Little, Lorraine and Duranteau, Jacques and Huet, Olivier and Haddad, Samir and Arabi, Yaseen},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: LWW},\n\tpages = {449--456},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Effect sizes in ongoing randomized controlled critical care trials.\n \n \n \n\n\n \n Ridgeon, E. E; Bellomo, R.; Aberegg, S. K; Mac Sweeney, R.; Varughese, R. S; Landoni, G.; and Young, P. J\n\n\n \n\n\n\n Critical Care, 21(1): 132. 2017.\n Number: 1 Publisher: BioMed Central\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{ridgeon_effect_2017,\n\ttitle = {Effect sizes in ongoing randomized controlled critical care trials},\n\tvolume = {21},\n\tissn = {1364-8535},\n\tnumber = {1},\n\tjournal = {Critical Care},\n\tauthor = {Ridgeon, Elliott E and Bellomo, Rinaldo and Aberegg, Scott K and Mac Sweeney, Rob and Varughese, Rachel S and Landoni, Giovanni and Young, Paul J},\n\tyear = {2017},\n\tnote = {Number: 1\nPublisher: BioMed Central},\n\tpages = {132},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial.\n \n \n \n\n\n \n Thomas, R.; Fysh, E. T H; Smith, N. A; Lee, P.; Kwan, B. C H; Yap, E.; Horwood, F. C; Piccolo, F.; Lam, D. C L; and Garske, L. A\n\n\n \n\n\n\n Jama, 318(19): 1903–1912. 2017.\n Number: 19 Publisher: American Medical Association\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{thomas_effect_2017,\n\ttitle = {Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the {AMPLE} randomized clinical trial},\n\tvolume = {318},\n\tissn = {0098-7484},\n\tnumber = {19},\n\tjournal = {Jama},\n\tauthor = {Thomas, Rajesh and Fysh, Edward T H and Smith, Nicola A and Lee, Pyng and Kwan, Benjamin C H and Yap, Elaine and Horwood, Fiona C and Piccolo, Francesco and Lam, David C L and Garske, Luke A},\n\tyear = {2017},\n\tnote = {Number: 19\nPublisher: American Medical Association},\n\tpages = {1903--1912},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Effect of 0.9% saline or Plasma-Lyte 148 as crystalloid fluid therapy in the intensive care unit on blood product use and postoperative bleeding after cardiac surgery.\n \n \n \n\n\n \n Reddy, S. K; Bailey, M. J; Beasley, R. W; Bellomo, R.; Mackle, D. M; Psirides, A. J; and Young, P. J\n\n\n \n\n\n\n Journal of cardiothoracic and vascular anesthesia, 31(5): 1630–1638. 2017.\n Number: 5 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{reddy_effect_2017,\n\ttitle = {Effect of 0.9\\% saline or {Plasma}-{Lyte} 148 as crystalloid fluid therapy in the intensive care unit on blood product use and postoperative bleeding after cardiac surgery},\n\tvolume = {31},\n\tissn = {1053-0770},\n\tnumber = {5},\n\tjournal = {Journal of cardiothoracic and vascular anesthesia},\n\tauthor = {Reddy, Sumeet K and Bailey, Michael J and Beasley, Richard W and Bellomo, Rinaldo and Mackle, Diane M and Psirides, Alex J and Young, Paul J},\n\tyear = {2017},\n\tnote = {Number: 5\nPublisher: Elsevier},\n\tpages = {1630--1638},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma.\n \n \n \n\n\n \n Fingleton, J.; Hardy, J.; Baggott, C.; Pilcher, J.; Corin, A.; Hancox, R. J; Harwood, M.; Holliday, M.; Reddel, H. K; and Shirtcliffe, P.\n\n\n \n\n\n\n BMJ open respiratory research, 4(1): e000217. 2017.\n Number: 1 Publisher: Archives of Disease in childhood\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fingleton_description_2017,\n\ttitle = {Description of the protocol for the {PRACTICAL} study: a randomised controlled trial of the efficacy and safety of {ICS}/{LABA} reliever therapy in asthma},\n\tvolume = {4},\n\tissn = {2052-4439},\n\tnumber = {1},\n\tjournal = {BMJ open respiratory research},\n\tauthor = {Fingleton, James and Hardy, Jo and Baggott, Christina and Pilcher, Janine and Corin, Andrew and Hancox, Robert J and Harwood, Matire and Holliday, Mark and Reddel, Helen K and Shirtcliffe, Philippa},\n\tyear = {2017},\n\tnote = {Number: 1\nPublisher: Archives of Disease in childhood},\n\tpages = {e000217},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma.\n \n \n \n\n\n \n Caswell-Smith, R.; Cripps, T.; Charles, T.; Hosking, A.; Handigol, M.; Holweg, C.; Matthews, J; Holliday, M.; Maillot, C.; Fingleton, J.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Allergy, Asthma & Clinical Immunology, 13. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{caswell-smith_day-time_2017,\n\ttitle = {Day-time variation of serum periostin in asthmatic adults treated with {ICS}/{LABA} and adults without asthma},\n\tvolume = {13},\n\tdoi = {10.1186/s13223-017-0182-0},\n\tjournal = {Allergy, Asthma \\& Clinical Immunology},\n\tauthor = {Caswell-Smith, Rachel and Cripps, Terrianne and Charles, Thomas and Hosking, Alexander and Handigol, Meghana and Holweg, Cécile and Matthews, J and Holliday, Mark and Maillot, Corentin and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Co-enrolment for the TAME and TTM-2 trials: the cerebral option.\n \n \n \n\n\n \n Parke, R. L; McGuinness, S.; Eastwood, G. M; Nichol, A.; Nielsen, N.; Dankiewicz, J.; and Bellomo, R.\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(2): 99. 2017.\n Number: 2 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{parke_co-enrolment_2017,\n\ttitle = {Co-enrolment for the {TAME} and {TTM}-2 trials: the cerebral option},\n\tvolume = {19},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Parke, Rachael L and McGuinness, Shay and Eastwood, Glenn M and Nichol, Alistair and Nielsen, Niklas and Dankiewicz, Josef and Bellomo, Rinaldo},\n\tyear = {2017},\n\tnote = {Number: 2\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {99},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n BTS guideline for oxygen use in adults in healthcare and emergency settings.\n \n \n \n\n\n \n O'driscoll, B R; Howard, L S; Earis, J; and Mak, V\n\n\n \n\n\n\n Thorax, 72(Suppl 1): ii1–ii90. 2017.\n Number: Suppl 1 Publisher: BMJ Publishing Group Ltd\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{odriscoll_bts_2017,\n\ttitle = {{BTS} guideline for oxygen use in adults in healthcare and emergency settings},\n\tvolume = {72},\n\tissn = {0040-6376},\n\tnumber = {Suppl 1},\n\tjournal = {Thorax},\n\tauthor = {O'driscoll, B R and Howard, L S and Earis, J and Mak, V},\n\tyear = {2017},\n\tnote = {Number: Suppl 1\nPublisher: BMJ Publishing Group Ltd},\n\tpages = {ii1--ii90},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Cause and Timing of Death and Subgroup Differential Effects of Erythropoietin in the EPO-TBI Study.\n \n \n \n\n\n \n Benedict Skrifvars, M.; French, C.; Bailey, M.; Presneill, J.; Nichol, A.; Little, L.; Duranteau, J.; Huet, O.; Haddad, S.; Arabi, Y.; McArthur, C.; James Cooper, D; and Bellomo, R.\n\n\n \n\n\n\n Journal of Neurotrauma, 35. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{benedict_skrifvars_cause_2017,\n\ttitle = {Cause and {Timing} of {Death} and {Subgroup} {Differential} {Effects} of {Erythropoietin} in the {EPO}-{TBI} {Study}},\n\tvolume = {35},\n\tdoi = {10.1089/neu.2017.5135},\n\tjournal = {Journal of Neurotrauma},\n\tauthor = {Benedict Skrifvars, Markus and French, Craig and Bailey, Michael and Presneill, Jeffrey and Nichol, Alistair and Little, Lorraine and Duranteau, Jacques and Huet, Olivier and Haddad, Samir and Arabi, Yaseen and McArthur, Colin and James Cooper, D and Bellomo, Rinaldo},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Body Mass Index and vigorous physical activity in children and adolescents: an international cross-sectional study.\n \n \n \n\n\n \n Braithwaite, I.; Stewart, A.; J Hancox, R.; Murphy, R.; Wall, C.; Beasley, R.; and Mitchell, E.\n\n\n \n\n\n\n Acta paediatrica (Oslo, Norway : 1992), 106. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{braithwaite_body_2017,\n\ttitle = {Body {Mass} {Index} and vigorous physical activity in children and adolescents: an international cross-sectional study},\n\tvolume = {106},\n\tdoi = {10.1111/apa.13903},\n\tjournal = {Acta paediatrica (Oslo, Norway : 1992)},\n\tauthor = {Braithwaite, Irene and Stewart, Alistair and J Hancox, Robert and Murphy, Rinki and Wall, Clare and Beasley, Richard and Mitchell, Edwin},\n\tyear = {2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Beta-agonist overuse and delay in obtaining medical review in high risk asthma: A secondary analysis of data from a randomised controlled trial.\n \n \n \n \n\n\n \n Pilcher, J.; Patel, M.; Pritchard, A.; Thayabaran, D.; Ebmeier, S.; Shaw, D.; Black, P.; Braithwaite, I.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n npj Primary Care Respiratory Medicine, 27(1): 1–7. 2017.\n Number: 1 Publisher: Springer US\n\n\n\n
\n\n\n\n \n \n \"Beta-agonistPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pilcher_beta-agonist_2017,\n\ttitle = {Beta-agonist overuse and delay in obtaining medical review in high risk asthma: {A} secondary analysis of data from a randomised controlled trial},\n\tvolume = {27},\n\tissn = {20551010},\n\turl = {http://dx.doi.org/10.1038/s41533-017-0032-z},\n\tdoi = {10.1038/s41533-017-0032-z},\n\tabstract = {Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or fixed dose budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The thresholds for high, marked and extreme beta-agonist use days were defined in the single maintenance and reliever therapy arm as: {\\textbackslash}textgreater8, {\\textbackslash}textgreater12 and {\\textbackslash}textgreater16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard arm as: {\\textbackslash}textgreater16, {\\textbackslash}textgreater24 and {\\textbackslash}textgreater32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48h of an overuse episode was determined by review of data collected during the study by participant report. The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48h was 0.94(0.20), 0.94(0.15) and 0.94(0.17), and 0.92(0.19), 0.90(0.26) and 0.94(0.15) for single maintenance and reliever therapy and Standard regimens, respectively. In at least 90\\% of days, in which beta-agonist overuse occurred, patients did not obtain medical review within 48h of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist regimen., RELIEVER INHALER OVERUSE AND DELAY IN MEDICAL REVIEW IN ASTHMA: In asthma, overuse of beta-agonist reliever medication and delay in seeking medical review in an exacerbation are linked to asthma deaths. Janine Pilcher at the Medical Research Institute of New Zealand, and co-workers, conducted a review of data from a study of 303 adult patients with severe asthma, followed over 24 weeks. The patients were allocated to either a budesonide/formoterol, or a salbutamol inhaler to take for symptom relief, in addition to their maintenance treatment. Inhalers were fitted with electronic monitors, to accurately document every use. In both groups, on 90\\% of days when an exacerbation requiring excess use of an inhaler occurred, patients did not follow-up with medical professionals within 48h as advised. Further, in both groups, 'extreme' reliever inhaler use was recorded at least once in around one in four patients.},\n\tnumber = {1},\n\tjournal = {npj Primary Care Respiratory Medicine},\n\tauthor = {Pilcher, Janine and Patel, Mitesh and Pritchard, Alison and Thayabaran, Darmiga and Ebmeier, Stefan and Shaw, Dominick and Black, Peter and Braithwaite, Irene and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tpmid = {28496190},\n\tnote = {Number: 1\nPublisher: Springer US},\n\tpages = {1--7},\n}\n\n
\n
\n\n\n
\n Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or fixed dose budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The thresholds for high, marked and extreme beta-agonist use days were defined in the single maintenance and reliever therapy arm as: \\textgreater8, \\textgreater12 and \\textgreater16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard arm as: \\textgreater16, \\textgreater24 and \\textgreater32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48h of an overuse episode was determined by review of data collected during the study by participant report. The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48h was 0.94(0.20), 0.94(0.15) and 0.94(0.17), and 0.92(0.19), 0.90(0.26) and 0.94(0.15) for single maintenance and reliever therapy and Standard regimens, respectively. In at least 90% of days, in which beta-agonist overuse occurred, patients did not obtain medical review within 48h of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist regimen., RELIEVER INHALER OVERUSE AND DELAY IN MEDICAL REVIEW IN ASTHMA: In asthma, overuse of beta-agonist reliever medication and delay in seeking medical review in an exacerbation are linked to asthma deaths. Janine Pilcher at the Medical Research Institute of New Zealand, and co-workers, conducted a review of data from a study of 303 adult patients with severe asthma, followed over 24 weeks. The patients were allocated to either a budesonide/formoterol, or a salbutamol inhaler to take for symptom relief, in addition to their maintenance treatment. Inhalers were fitted with electronic monitors, to accurately document every use. In both groups, on 90% of days when an exacerbation requiring excess use of an inhaler occurred, patients did not follow-up with medical professionals within 48h as advised. Further, in both groups, 'extreme' reliever inhaler use was recorded at least once in around one in four patients.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Asthma prescribing: W here are we headed?.\n \n \n \n\n\n \n Beasley, R.; Hardy, J.; and Hancox, R.\n\n\n \n\n\n\n Respirology, 22(8): 1487–1488. 2017.\n Number: 8 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_asthma_2017,\n\ttitle = {Asthma prescribing: {W} here are we headed?},\n\tvolume = {22},\n\tissn = {1323-7799},\n\tnumber = {8},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Hardy, Jo and Hancox, Robert},\n\tyear = {2017},\n\tnote = {Number: 8\nPublisher: Wiley Online Library},\n\tpages = {1487--1488},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Birth weight and subsequent body mass index in children: an international cross‐sectional study.\n \n \n \n\n\n \n Mitchell, E A; Stewart, A W; Braithwaite, I; Hancox, R J; Murphy, R.; Wall, C.; Beasley, R; and Group, I. P. T. S.\n\n\n \n\n\n\n Pediatric obesity, 12(4): 280–285. 2017.\n Number: 4 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mitchell_birth_2017,\n\ttitle = {Birth weight and subsequent body mass index in children: an international cross‐sectional study},\n\tvolume = {12},\n\tissn = {2047-6302},\n\tnumber = {4},\n\tjournal = {Pediatric obesity},\n\tauthor = {Mitchell, E A and Stewart, A W and Braithwaite, I and Hancox, R J and Murphy, Rinki and Wall, Clare and Beasley, R and Group, ISAAC Phase Three Study},\n\tyear = {2017},\n\tnote = {Number: 4\nPublisher: Wiley Online Library},\n\tpages = {280--285},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.\n \n \n \n\n\n \n Udy, A. A; Dulhunty, J. M; Roberts, J. A; Davis, J. S; Webb, S. A R; Bellomo, R.; Gomersall, C.; Shirwadkar, C.; Eastwood, G. M; and Myburgh, J.\n\n\n \n\n\n\n International journal of antimicrobial agents, 49(5): 624–630. 2017.\n Number: 5 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{udy_association_2017,\n\ttitle = {Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the {BLING}-{II} randomised, placebo-controlled, clinical trial},\n\tvolume = {49},\n\tissn = {0924-8579},\n\tnumber = {5},\n\tjournal = {International journal of antimicrobial agents},\n\tauthor = {Udy, Andrew A and Dulhunty, Joel M and Roberts, Jason A and Davis, Joshua S and Webb, Steven A R and Bellomo, Rinaldo and Gomersall, Charles and Shirwadkar, Charudatt and Eastwood, Glenn M and Myburgh, John},\n\tyear = {2017},\n\tnote = {Number: 5\nPublisher: Elsevier},\n\tpages = {624--630},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n An audit of coagulation screening in patients presenting to the emergency department for potential stroke thrombolysis.\n \n \n \n\n\n \n Thorne, K.; McNaughton, H.; and Weatherall, M.\n\n\n \n\n\n\n Internal medicine journal, 47(2): 189–193. 2017.\n Number: 2 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{thorne_audit_2017-1,\n\ttitle = {An audit of coagulation screening in patients presenting to the emergency department for potential stroke thrombolysis},\n\tvolume = {47},\n\tissn = {1444-0903},\n\tnumber = {2},\n\tjournal = {Internal medicine journal},\n\tauthor = {Thorne, Katie and McNaughton, Harry and Weatherall, Mark},\n\tyear = {2017},\n\tnote = {Number: 2\nPublisher: Wiley Online Library},\n\tpages = {189--193},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Angiotensin II for the treatment of vasodilatory shock.\n \n \n \n\n\n \n Khanna, A.; English, S. W; Wang, X. S; Ham, K.; Tumlin, J.; Szerlip, H.; Busse, L. W; Altaweel, L.; Albertson, T. E; and Mackey, C.\n\n\n \n\n\n\n New England Journal of Medicine, 377(5): 419–430. 2017.\n Number: 5 Publisher: Mass Medical Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{khanna_angiotensin_2017-1,\n\ttitle = {Angiotensin {II} for the treatment of vasodilatory shock},\n\tvolume = {377},\n\tissn = {0028-4793},\n\tnumber = {5},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Khanna, Ashish and English, Shane W and Wang, Xueyuan S and Ham, Kealy and Tumlin, James and Szerlip, Harold and Busse, Laurence W and Altaweel, Laith and Albertson, Timothy E and Mackey, Caleb},\n\tyear = {2017},\n\tnote = {Number: 5\nPublisher: Mass Medical Soc},\n\tpages = {419--430},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Age of red cells for transfusion and outcomes in critically ill adults.\n \n \n \n\n\n \n Cooper, D J.; McQuilten, Z. K; Nichol, A.; Ady, B.; Aubron, C.; Bailey, M.; Bellomo, R.; Gantner, D.; Irving, D. O; and Kaukonen, K.\n\n\n \n\n\n\n New England Journal of Medicine, 377(19): 1858–1867. 2017.\n Number: 19 Publisher: Mass Medical Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{cooper_age_2017-1,\n\ttitle = {Age of red cells for transfusion and outcomes in critically ill adults},\n\tvolume = {377},\n\tissn = {0028-4793},\n\tnumber = {19},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Cooper, D James and McQuilten, Zoe K and Nichol, Alistair and Ady, Bridget and Aubron, Cécile and Bailey, Michael and Bellomo, Rinaldo and Gantner, Dashiell and Irving, David O and Kaukonen, Kirsi-Maija},\n\tyear = {2017},\n\tnote = {Number: 19\nPublisher: Mass Medical Soc},\n\tpages = {1858--1867},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Adult asthma quick reference guides: Trans-Tasman differences in opinion.\n \n \n \n\n\n \n Beasley, R.; Thayabaran, D.; and Hancox, R. J.\n\n\n \n\n\n\n Respirology, 22(1): 9–11. 2017.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{beasley_adult_2017,\n\ttitle = {Adult asthma quick reference guides: {Trans}-{Tasman} differences in opinion},\n\tvolume = {22},\n\tissn = {14401843},\n\tdoi = {10.1111/resp.12935},\n\tnumber = {1},\n\tjournal = {Respirology},\n\tauthor = {Beasley, Richard and Thayabaran, Darmiga and Hancox, Robert J.},\n\tyear = {2017},\n\tnote = {Number: 1},\n\tkeywords = {asthma, clinical guideline, inhaled corticosteroid, long-acting beta-2 agonist},\n\tpages = {9--11},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Admitting elderly patients to icu: Is it just about survival?.\n \n \n \n\n\n \n Ritzema, J.; and Young, P.\n\n\n \n\n\n\n New Zealand Medical Journal, 130(1453): 9–10. 2017.\n Number: 1453\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{ritzema_admitting_2017,\n\ttitle = {Admitting elderly patients to icu: {Is} it just about survival?},\n\tvolume = {130},\n\tissn = {11758716},\n\tnumber = {1453},\n\tjournal = {New Zealand Medical Journal},\n\tauthor = {Ritzema, Jay and Young, Paul},\n\tyear = {2017},\n\tnote = {Number: 1453},\n\tpages = {9--10},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n A priori consent within pragmatic randomised controlled trials: A web-based survey of statin use in primary care.\n \n \n \n\n\n \n Semprini, A.; Hills, T.; Braithwaite, I.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Innovations, 3: bmjinnov–2017. 2017.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{semprini_priori_2017,\n\ttitle = {A priori consent within pragmatic randomised controlled trials: {A} web-based survey of statin use in primary care},\n\tvolume = {3},\n\tdoi = {10.1136/bmjinnov-2017-000193},\n\tjournal = {BMJ Innovations},\n\tauthor = {Semprini, Alex and Hills, Thomas and Braithwaite, Irene and Weatherall, Mark and Beasley, Richard},\n\tyear = {2017},\n\tpages = {bmjinnov--2017},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n A cross-sectional survey of Australian and New Zealand public opinion on methods to triage intensive care patients in an influenza pandemic.\n \n \n \n\n\n \n Cheung, W.; Myburgh, J.; McGuinness, S.; Chalmers, D.; Parke, R.; Blyth, F.; Seppelt, I.; Parr, M.; Hooker, C.; and Blackwell, N.\n\n\n \n\n\n\n Critical Care and Resuscitation, 19(3): 254. 2017.\n Number: 3 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{cheung_cross-sectional_2017,\n\ttitle = {A cross-sectional survey of {Australian} and {New} {Zealand} public opinion on methods to triage intensive care patients in an influenza pandemic},\n\tvolume = {19},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Cheung, Winston and Myburgh, John and McGuinness, Shay and Chalmers, Debra and Parke, Rachael and Blyth, Fiona and Seppelt, Ian and Parr, Michael and Hooker, Claire and Blackwell, Nikki},\n\tyear = {2017},\n\tnote = {Number: 3\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {254},\n}\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);